Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

Dr. Marc Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of ...

Great Bay Bio (GBB) announced today the first close of its Series B financing round, led by a strategic investment ...

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and ...

The acquisition is expected to be completed in the coming days.

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and ...

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys ...